Pressemitteilung BoxID: 220747 (Geratherm Medical AG)
  • Geratherm Medical AG
  • Fahrenheitstrasse 1
  • 98716 Geschwenda
  • Ansprechpartner
  • Albert Hirtz
  • +49 (6331) 698998

Study at University Hospital Münster and the St. Johannes Hospital Dortmund examined the Method "Stroke Risk Analysis (SRA)" of apoplex medical technologies GmbH

(lifePR) (Geschwenda, ) The study has been published in the Journal of Clinical and Experimental Cardiology under the title "Extended electrocardiographic Poincaré analysis (EPA) for better identification of patients with paroxysmal atrial fibrillation" at the 4th of March 2011.

The study represents a retrospective validation of the SRA process (Stroke Risk Analysis) of apoplex medical technologies GmbH, Pirmasens. In the publication, the SRA process is called EPA (Extended Electrocardiographic Poincaré Analysis) to indicate the kind of mathematical analysis. EPA includes the entire SRA process and all its algorithms.

Link to study publication Abstract

Background: Atrial fibrillation (AF) - be it permanent or paroxysmal - is the most frequent and most effectively treatable cause of stroke. However, when paroxysmal, even electrocardiography for 24 hours (24h‐ECG) misses AF in more than 50% of cases. We assessed whether extended Poincaré analysis of ECG R‐R intervals (EPA) can help to identify electrocardiographic remodeling suggestive of paroxysmal AF (PAF).

Methods: Twenty‐nine patients with previously diagnosed PAF were re‐assessed by 24h‐ECG using conventional analysis and EPA based on a previously trained algorithm considering among other ratios of R‐R interval duration, number of premature atrial complexes, approximate entropy, and standard deviation of Poincaré plots‐axes. 24h‐ECG from 21 healthy subjects without a history of AF served as negative, and 9 patients with permanent AF as positive controls.

Results: PAF during 24h‐ECG was detected in 4 out of 29 (14%) patients with a history of PAF by conventional analysis. EPA classified ECGs of these and 22 additional patients with a history of PAF, i.e. a total 90%, as suggestive of PAF. All patients with permanent AF were identified by both tools. EPA additionally classified the ECG in 4 out of 21 control subjects as suggestive of PAF.

Conclusions: Extended Poincaré analysis in patients with a history of PAF is more sensitive to electrocardiographic abnormalities than is conventional 24h‐ ECG analysis. These findings warrant prospective studies of EPA in patients with a high likelihood of PAF, i.e. with stroke of undetermined origin.

Additional study results about the use of apoplex‐products

Prospective study with SRAclinic at the neurological department of the university hospital Heidelberg. Principal investigator is Professor Dr. R. Veltkamp.

Continuous Stroke Unit ECG Monitoring Detects Intermittent Atrial Fibrillation more Sensitively than 24 h Holter ECG after Acute Stroke and TIA The results will be presented for the first time on May 26th 2011 at the XX. European Stroke Conference (ESC) in Hamburg.

Supplementary information about apoplex medical technologies

apoplex medical technologies GmbH was founded in 2004 in Pirmasens, in the west of the Rhineland‐Palatinate, and, within the field of medical technology, specializes in new and innovative technological products for the prevention of strokes throughout the world. The subsidiary of Geratherm Medical AG focuses on easily applicable and efficient methods of patient screening using medical‐technical applications to prevent strokes and vascular dementia. The SRA (Stroke Risk Analysis) procedure is the first practicable screening method for paroxysmal atrial fibrillation. It is available in versions for use in medical practices and stroke units. apoplex medical technologies is supported by an extensive academic and clinical network, which professionally supplements its own core competences in the fields of mathematics, physics and medicine.

Further information is available at